Targeted therapy combination effective for patients with advanced cholangiocarcinoma and BRAF mutations
(University of Texas M. D. Anderson Cancer Center) In a Phase II trial led by MD Anderson researchers, a combination targeted therapy acheived a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 17, 2020 Category: Cancer & Oncology Source Type: news

Mesothelioma T-Cell Therapy Shows Early Effectiveness in Trial
A mesothelioma clinical trial involving genetically modified T cells has opened to considerable acclaim, shrinking tumors in the first five patients who were treated. The phase I portion of the clinical trial is designed to define the safety profile and optimal dosage level of TC-210, a novel immunotherapy targeting mesothelin, a cell-surface protein often overexpressed in several cancers. While T cell modifications in the laboratory are proving safe and well tolerated, the initial signs of consistent efficacy became an early bonus in phase I. Four of the patients treated had mesothelioma. The fifth had ovarian cancer. All...
Source: Asbestos and Mesothelioma News - August 4, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news

Scientists discover a new mechanism controlling liver cancer development
This study, published in PNAS, shows that the PPARα protein, when blocked, dramatically reduces the impact and progression of cholangiocarcinoma (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 1, 2020 Category: Cancer & Oncology Source Type: news

Ivosidenib Promising Against Refractory Bile Duct Cancer Ivosidenib Promising Against Refractory Bile Duct Cancer
Ivosidenib improved progression-free survival in patients with previously treated isocitrate dehydrogenase 1 (IDH1)-mutant cholangiocarcinoma in a phase 3 placebo-controlled trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Pemazyre Approved for Treatment of Advanced Cholangiocarcinoma
Title: Pemazyre Approved for Treatment of Advanced CholangiocarcinomaCategory: Health NewsCreated: 4/21/2020 12:00:00 AMLast Editorial Review: 4/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 21, 2020 Category: Cancer & Oncology Source Type: news

Pemazyre Approved for Treatment of Advanced Cholangiocarcinoma
MONDAY, April 20, 2020 -- Pemazyre (pemigatinib) has been granted accelerated approval for the treatment of advanced cholangiocarcinoma, the U.S. Food and Drug Administration announced Friday. The drug approval is indicated for previously treated... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 20, 2020 Category: General Medicine Source Type: news

FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion
Oncology News burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 20, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves First Targeted Drug for Bile Duct Cancer FDA Approves First Targeted Drug for Bile Duct Cancer
A subgroup of patients with advanced cholangiocarcinma who have tumors with FGFR2 abnormalities have a new treatment option -- the oral targeted therapy pemigatinib.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 20, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Pemigatinib for Advanced Cholangiocarcinoma
This is the first FDA approval for this patient population. (Source: CancerNetwork)
Source: CancerNetwork - April 18, 2020 Category: Cancer & Oncology Authors: Brielle Benyon Source Type: news

FDA Approves Pemazyre (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 17, 2020-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre (pemigatinib), a kinase inhibitor indicated for the treatment of adults with previously... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 18, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves First Targeted Treatment for Patients with Cholangiocarcinoma, a Cancer of Bile Ducts
FDA has approved Pemazyre (pemigatinib), the first treatment approved for adults with certain types of previously treated, advanced cholangiocarcinoma, a rare form of cancer that forms in bile ducts. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Bile duct cancer: Mayo Clinic Radio Health Minute
In this Mayo Clinic Radio Health Minute, Dr. Bret Petersen, a Mayo Clinic?gastroenterologist, discusses bile duct cancer. To listen, click the link below. Bile duct cancer (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 20, 2020 Category: Databases & Libraries Source Type: news

Gravely ill mother diagnosed with bile duct cancer gets new lease of life from revolutionary drug
Mother-of-four Kadiatou Diallo, who is originally from Guinea in West Africa and has lived in the UK for nearly 20 years, is feeling better than she has done in years as a result of taking the new drug. (Source: the Mail online | Health)
Source: the Mail online | Health - March 14, 2020 Category: Consumer Health News Source Type: news

Bile duct cancer treatment potential boost from tailored medication -- study
(University of Birmingham) Treatment of patients suffering from bile duct cancer could be improved by tailoring medication to the levels of a key protein in people with the disease, according to new research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 14, 2020 Category: Cancer & Oncology Source Type: news

'Genetic rewiring' drives cancer's drug resistance
(Institute of Cancer Research) Tiny RNA molecule rewires signalling network in bile duct cancer. Drugs to block RNA could overcome cancer's drug resistance. Findings announced to coincide with Bile Duct Cancer Awareness Day. Results could be applicable in other cancer types and have wider benefit. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 11, 2020 Category: Cancer & Oncology Source Type: news

Study suggests new strategy for treating advanced, progressing bile duct cancer
(Ohio State University Wexner Medical Center) A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) shows how resistance to a promising targeted drug develops in patients with a rare, lethal cancer of the bile ducts called cholangiocarcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 14, 2020 Category: Cancer & Oncology Source Type: news

FDA Grants Priority Review to Pemigatinib for Subgroup
The FDA has granted a priority review to a new drug application for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements. (Source: CancerNetwork)
Source: CancerNetwork - December 2, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib in Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements
SUZHOU, China, Dec. 1, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ( " Innovent " or " the Company " ) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 1, 2019 Category: Drugs & Pharmacology Source Type: news

Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma
WILMINGTON, Del.--(BUSINESS WIRE)--Nov. 27, 2019-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) for pemigatinib, a selective... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 27, 2019 Category: Drugs & Pharmacology Source Type: news

' Unprecedented' Results in Biliary Tract Cancer'Unprecedented' Results in Biliary Tract Cancer
Experts were impressed with results from a phase 3 study of a targeted agent in a subgroup of patients with cholangiocarcinoma with genetic mutations.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 3, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

#MayoClinicRadio podcast: 6/1/19
Listen: Mayo Clinic Radio 6/1/19 On the Mayo Clinic Radio podcast, Dr. Brent Bauer, director of research for the Mayo Clinic Integrative Medicine Program, shares how complementary medicine, also known as integrative medicine, is used in cancer care. Also on the podcast, Dr. Bret Petersen, a Mayo Clinic gastroenterologist, discusses treatment for bile duct cancer. And Dr. Randall DeMartino, a Mayo [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - June 3, 2019 Category: Databases & Libraries Source Type: news

Blood Test Could Spot Multiple Cancer Types, Researchers Say
WEDNESDAY, May 29, 2019 -- A gene-based blood test can accurately detect breast, colorectal, lung, ovarian, pancreatic, gastric or bile duct cancers in patients, researchers report. The test uses artificial intelligence to identify and interpret... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 29, 2019 Category: General Medicine Source Type: news

AI singles out high-risk prostate cancer on mpMRI
Working with radiomics data on multiparametric MRI (mpMRI) scans, an artificial...Read more on AuntMinnie.comRelated Reading: Advanced imaging offers insight into targeted therapies AI can predict breast cancer molecular subtypes on MRI AI can differentiate glioblastoma, brain metastasis CT radiomics improves management of bile duct cancer Faster MRI protocol avoids unneeded prostate biopsies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 8, 2019 Category: Radiology Source Type: news

Gene-editing tool CRISPR/Cas9 shown to limit impact of certain parasitic diseases
(George Washington University) For the first time, researchers at the George Washington University have successfully used the gene-editing tool CRISPR/Cas9 to limit the impact of parasitic worms responsible for schistosomiasis and for liver fluke infection, which can cause a diverse spectrum of human disease including bile duct cancer.   (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 15, 2019 Category: Cancer & Oncology Source Type: news

CT radiomics improves management of bile duct cancer
Researchers from China have developed a radiomics model that can determine...Read more on AuntMinnie.comRelated Reading: Radiomics helps distinguish lung cancer nodules on CT AIUM: Can deep learning classify liver fibrosis on US? AI, radiomics help distinguish lung nodules on CT scans MRI, radiomics help diagnose, discern ADHD subtypes AAPM: Radiomics helps fine-tune radiation therapy dose (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 19, 2018 Category: Radiology Source Type: news

Single Agent Treats Two Cancers With Same Genetic Cause
Pembrolizumab treated colon cancer, intrahepatic cholangiocarcinoma in patient with Lynch syndrome (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 27, 2018 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Pharmacy, Journal, Source Type: news

GW Researcher investigating link between parasitic infection and bile duct cancer
(George Washington University) Paul Brindley, Ph.D., at the GW School of Medicine and Health Sciences, has received more than $1.7 million from the National Cancer Institute at the National Institutes of Health to investigate the cellular and molecular links between liver fluke infection and bile duct cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 5, 2018 Category: International Medicine & Public Health Source Type: news

Bile duct cancer symptoms: Eight signs of the deadly disease you need to watch out for
BILE duct cancer is a rare form of cancer but it ’s important to recognise all the signs as soon as possible, for in the later stages of the disease no cure is possible. There are eight signs to look out for. (Source: Daily Express - Health)
Source: Daily Express - Health - August 22, 2018 Category: Consumer Health News Source Type: news

Stefan Karl Stefansson dead: LazyTown actor dies - what is bile duct cancer?
STEFAN KARL STEFANSSON, the LazyTown actor that starred as Robbie Rotten, has died after a battle with bile duct cancer. Bile duct cancer symptoms include  itchy skin and weight loss - these are the warning signs to look out for. (Source: Daily Express - Health)
Source: Daily Express - Health - August 22, 2018 Category: Consumer Health News Source Type: news

'Rapid autopsy' races the clock to unlock mysteries of cancer
After Keith Beck died of bile duct cancer last year, family members said more than 900 people showed up to pay respects to the popular athletic director at the University of Findlay in northwestern Ohio. (Source: CNN.com - Health)
Source: CNN.com - Health - May 3, 2018 Category: Consumer Health News Source Type: news

'Rapid autopsy' to unlock mysteries of cancer
After Keith Beck died of bile duct cancer last year, family members said more than 900 people showed up to pay respects to the popular athletic director at the University of Findlay in northwestern Ohio. (Source: CNN.com - Health)
Source: CNN.com - Health - May 3, 2018 Category: Consumer Health News Source Type: news

How a New Kind of Autopsy Is Helping in the Fight Against Cancer
After Keith Beck died of bile duct cancer last year, family members said, more than 900 people showed up to pay respects to the popular athletic director at the University of Findlay in northwestern Ohio. Many were former students who recalled acts of kindness during Beck’s nearly 30-year career: $20 given to a kid who was broke, textbooks bought for a student whose parents were going through bankruptcy, a spot cleared to sleep on Beck’s living room floor. But few knew about Beck’s final gesture of generosity. The 59-year-old had agreed to a “rapid autopsy,” a procedure conducted within hours ...
Source: TIME: Health - April 24, 2018 Category: Consumer Health News Authors: JoNel Aleccia / Kaiser Health News Tags: Uncategorized Cancer healthytime Source Type: news

First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple
(University of Texas M. D. Anderson Cancer Center) A phase I, first-in-human study led by The University of Texas MD Anderson Cancer Center reveals for the first time, an investigational drug that is effective and safe for patients with cancers caused by an alteration in the receptor tyrosine kinase known as RET. The drug appears to be promising as a potential therapy for RET-driven cancers, such as medullary and papillary thyroid, non-small cell lung, colorectal and bile duct cancers, which have been historically difficult to treat. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2018 Category: Cancer & Oncology Source Type: news

Bile Duct Cancer (Cholangiocarcinoma)
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - February 2, 2018 Category: General Medicine Source Type: news

RedHill teams with Mayo Clinic, MD Anderson on new cancer trial
Tel-Aviv, Israel-based RedHill Biopharma (Nasdaq: RDHL) – which is continuing to build up its U.S. commercial operations based in Raleigh – is teaming with the Mayo Clinic and The University of Texas MD Anderson Cancer Center on a new cancer trial. The new Phase IIa study is for YELIVA – a product candidate RedHill acquired from Apogee Biotechnolo gy back in 2015 – for the treatment of cholangiocarcinoma, or bile duct cancer. It will enroll patients at Mayo Clinic campuses in both Arizona… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 28, 2017 Category: Pharmaceuticals Authors: Jennifer Henderson Source Type: news

Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma
GAITHERSBURG, Md., Dec. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Sirnaomics, Inc. (www.sirnaomics.com), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that the Office of Orphan Product De... Biopharmaceuticals, Oncology, FDA Sirnaomics, Cholangiocarcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 6, 2017 Category: Pharmaceuticals Source Type: news

PCI Biotech starts dosing in Phase I extension study for bile duct cancer
Norwegian biopharmaceutical firm PCI Biotech has started dosing patients in a Phase I extension study with fimaCHEM to treat inoperable perihilar bile duct cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - August 15, 2017 Category: Pharmaceuticals Source Type: news

Raw fish dishes in Thailand are full of deadly parasites
One of the major causes of bile duct cancer, which kills 20,000 Thais each year, is a parasitic flatworm native to the Mekong region and found in freshwater fish. (Source: the Mail online | Health)
Source: the Mail online | Health - June 28, 2017 Category: Consumer Health News Source Type: news

Avoid raw fish dishes during your holiday in Thailand!
One of the major causes of bile duct cancer, which kills 20,000 Thais each year, is a parasitic flatworm native to the Mekong region and found in freshwater fish. (Source: the Mail online | Health)
Source: the Mail online | Health - June 28, 2017 Category: Consumer Health News Source Type: news

How bile duct cancer develops and how it can be prevented
(German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)) What promotes the development of bile duct cancer in the liver? Are these factors different from those that are responsible for the much more common hepatocellular carcinomas? Scientists from the Heidelberg and Munich have been the first to uncover the molecular causes that selectively lead to the development of bile duct cancer in mice. The researchers also discovered that antioxidants or an inhibitor of a specific key enzyme can be used to stop this cancer-promoting process. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 12, 2017 Category: Cancer & Oncology Source Type: news

FISH Beneficial for Diagnosing Cholangiocarcinoma
FISH increased sensitivity of brush cytology for cholangiocarcinoma while preserving specificity (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 9, 2017 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pathology, Journal, Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
Title: Chemo Drug May Buy Time for Those With Bile Duct CancerCategory: Health NewsCreated: 5/18/2017 12:00:00 AMLast Editorial Review: 5/19/2017 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - May 19, 2017 Category: Cancer & Oncology Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
For patients with the rare disease, survival benefit was seen in those given Xeloda, researchers say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 19, 2017 Category: Cancer & Oncology Tags: Family Medicine, Gastroenterology, Nursing, Oncology, News, Source Type: news

Chemo Drug May Buy Time for Those with Bile Duct Cancer
For patients with the rare disease, survival benefit was seen in those given Xeloda, researchers say Source: HealthDay Related MedlinePlus Pages: Bile Duct Cancer, Cancer Chemotherapy (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 18, 2017 Category: Consumer Health News Source Type: news

Chemo Drug, Xeloda, May Buy Time for Those With Bile Duct Cancer
THURSDAY, May 18, 2017 -- The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer, a new study finds. People with bile duct cancer who received the medication lived for an average of about 17 months... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 18, 2017 Category: General Medicine Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
THURSDAY, May 18, 2017 -- The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer, a new study finds. People with bile duct cancer who received the medication lived for an average of about 17 months... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 18, 2017 Category: General Medicine Source Type: news

Chemo Drug May Buy Time for Those With Bile Duct Cancer
For patients with the rare disease, survival benefit was seen in those given Xeloda, researchers say (Source: Cancercompass News: Colorectal Cancer)
Source: Cancercompass News: Colorectal Cancer - May 18, 2017 Category: Cancer & Oncology Source Type: news

Capecitabine improves post-surgery survival period in bile duct cancer patients
A Cancer Research UK-funded trial (BILCAP) showed that the chemotherapy drug capecitabine increased the survival period of bile duct cancer patients by up to one and a half years after undergoing surgery for the disease. (Source: Drug Development Technology)
Source: Drug Development Technology - May 18, 2017 Category: Pharmaceuticals Source Type: news